EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger
CEO, Ron Weinberger
Source: EMVision
Market Herald logo


Be the first with the news that moves the market
  • EMVision Medical Devices (EMV) partners with Brisbane-based Metro South Health
  • The companies will advance EMV’s novel brain scanner technology into products that improve patient outcomes
  • Metro South Health will provide EMV with access to expertise, simulation rooms and hospital infrastructure, and will help with a clinical study
  • EMVision will contribute $215,500 over the one-year term to conduct research activities ahead of expanded clinical studies
  • Company shares are down 0.33 per cent and trading at $3 at 3.35 pm AEST

EMVision Medical Devices (EMV) has signed a clinical expertise, research and innovation collaboration with Metro South Health.

Together, the companies will continue to advance and translate EMV’s novel brain scanner imaging technology into products that improve patient outcomes.

Specifically, the partnership will include expert clinical advice, analysis and contributions to the design and development of devices, the bedside and pre-hospital workflows, the simulation of patient bedside care, the specifications, evaluation and use of the device, as well as end user acceptance testing.

Metro South Health is a public healthcare provider that runs five hospitals and a network of community health centres across Brisbane. Among the five hospital is the Princess Alexandra Hospital where most of the research activities under the partnership will be carried out. The hospital will therefore have access to EMVision’s latest technology.

“Collaboration of this kind for emerging medical device companies is a best practice model in countries with world leading health technology advances but is less prevalent in Australia. Metro South Health is following this best practice path while allowing EMVision exceptional access to a very large pool of clinical expertise that is unusual for a company of our size,” EMVision CEO Dr Ron Weinberger said.

The collaboration will span one year but may be renewed if both parties choose. EMVision will contribute $215,500 in research funding over the term.

Company shares were down 0.33 per cent and trading at $3 at 3.35 pm AEST.

EMV by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

" Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial

Dimerix (DXB) has been granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients.